Table of Contents The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis TATA India PHARMA & Healthcare Fund - G
Scheme Objective
CAGR return of 12.3% since its launch. Return for 2024 was 40.4% , 2023 was 36.6% and 2022 was -8% . NAV as on 19 May 25 ₹29.6917 ↑ 0.12 (0.40 %) Net Assets (AUM) as on 30 Apr 2025 ₹1,223 Cr. Launch Date 28 Dec 2015 Category Equity - Sectoral Rating Type Open Ended Fund Risk High AMC Tata Asset Management Limited Alpha Ratio 1.0 Expense Ratio 0.0 % Sharpe Ratio 0.521 Information Ratio 0.67 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 May 25 Duration Returns 1 Month 2.6% 3 Month 6.5% 6 Month 0.8% 1 Year 16.7% 3 Year 23.9% 5 Year 22.9% 10 Year 15 Year Since launch 12.3% Historical Annual Returns
Year Returns 2024 40.4% 2023 36.6% 2022 -8% 2021 19.1% 2020 64.4% 2019 5.5% 2018 -2.6% 2017 4.7% 2016 -14.7% Growth of 10k Over Years
Date Value 30 Apr 20 ₹10,000 30 Apr 21 ₹14,766 30 Apr 22 ₹15,521 30 Apr 23 ₹15,212 30 Apr 24 ₹23,213 30 Apr 25 ₹27,062 Asset Allocation
Asset Class Value Cash 6.59% Equity 93.41% Sector Allocation
Sector Value Health Care 91.11% Basic Materials 2.29% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMADrug Manufacturers - Specialty & Generic 13% ₹157 Cr 854,300
↑ 50,000 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 500087Drug Manufacturers - Specialty & Generic 6% ₹76 Cr 490,000 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMADrug Manufacturers - Specialty & Generic 6% ₹76 Cr 615,100
↓ -125,900 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSPMedical Care Facilities 6% ₹71 Cr 101,255 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 5% ₹64 Cr 104,965 Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | 500257Drug Manufacturers - Specialty & Generic 5% ₹64 Cr 303,240 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Oct 20 | 532843Medical Care Facilities 5% ₹59 Cr 855,100 Aster DM Healthcare Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Dec 22 | ASTERDMMedical Care Facilities 4% ₹48 Cr 956,991 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEMDrug Manufacturers - Specialty & Generic 3% ₹38 Cr 75,249 HealthCare Global Enterprises Ltd (Healthcare)
Equity, Since 31 Dec 18 | HCGMedical Care Facilities 3% ₹37 Cr 666,121
Talk to our investment specialistFund Managers
Name Since Tenure Meeta Shetty 9 Mar 21 4.15 Yr. Rajat Srivastava 16 Sep 24 0.62 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
Computer Age Management Services Ltd Address New No.10, Old No.178,,Kodambakkam High Road,,Opp. Hotel Palmgrove,,Nungambakkam FAX 91-44-28283610 Email enq_L@camsonline.com Administrator Companies
Company Address Tata Mutual Fund 1903, B-Wing, Parinee Crescenzo,,G-Block, Bandra Kurla Complex, Bandra East Mumbai 400051 Auditors
Company Address Deloitte Haskins & Sells LLP 12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate,,Worli M/s BSR & Co. KPMG House, Kamala Mills Compound,448 Senapati Bapat Marg,Lower Parel All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year TATA India Pharma & Healthcare Fund
Normal Dividend, Reinvestment ₹29.6917
↑ 0.12 0.77 % 16.65 % 23.89 % 22.87 % TATA India Pharma & Healthcare Fund
Normal Dividend, Payout ₹29.6917
↑ 0.12 0.77 % 16.65 % 23.89 % 22.87 % TATA India Pharma & Healthcare Fund
Growth ₹29.6917
↑ 0.12 0.77 % 16.65 % 23.89 % 22.87 % Data as on 19 May 25
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2025 Shepard Technologies Private Limited. All Rights Reserved